BioIVT Acquires XenoTech from Sekisui Chemical

September 12, 2022

BioIVT has acquired XenoTech, a Kansas City–based provider of ADME‑Tox in vitro models and contract research services, from Sekisui Chemical. The acquisition expands BioIVT's hepatic product portfolio and ADME/DMPK capabilities to better support biopharma customers' preclinical testing needs. Financial terms were not disclosed.

Buyers
BioIVT
Targets
XenoTech
Sellers
Sekisui Chemical
Industry
Biotechnology
Location
Kansas, United States
Transaction Type
Divestiture

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.